OOIR: Observatory of International Research

Papers

(The median citation count of Pharmacogenomics Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study	57
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States	41
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data	28
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform	23
Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors	22
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study	22
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study	21
Using ChatGPT to predict the future of personalized medicine	21
STRIPE partners in precision medicine series: provider perspective	21
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care	17
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population	16
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration	15
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients	15
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder	14
Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle	13
APF2: an improved ensemble method for pharmacogenomic variant effect prediction	12
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer	12
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing	12
Gene expression signatures predict response to therapy with growth hormone	11
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress	11
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients	11
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?	11
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis	11
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population	10
AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients	9

Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance	8
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder	7
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)	7
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects	7
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications	7
Polymorphisms at CYP enzymes, NR1I2 and NR1I3 in association with virologic response to antiretroviral therapy in Brazilian HIV-positive individuals	7
Genetic markers of early response to lurasidone in acute schizophrenia	7
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients	6
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics	6
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci	6
A blockchain-based framework to support pharmacogenetic data sharing	6
The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review	6
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study	6
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer	6
UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab	5
Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome	5
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis	4
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes	4
Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests	4
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application	4
Non-steroidal anti-inflammatory drug target gene associations with major depressive disorders: a Mendelian randomisation study integrating GWAS, eQTL and mQTL Data	4
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres	3
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone	3
Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis	3
Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection	3
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach	3
A NOS1AP gene variant is associated with a paradoxical increase of the QT-interval shortening effect of digoxin	3
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study	3
Whole-genome sequencing analysis of clozapine-induced myocarditis	3
DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?	3
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)	3
Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort	3
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug	3
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services	3
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial	2
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort	2
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis	2
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females	2
Cytochrome P450-2D6 activity in people with codeine use disorder	2
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?	2
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?	2
Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention	2
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population	2
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data	2
Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors	2
STRIPE partners in precision medicine series: pharmacist perspective	2
Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation	2